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Abstract
Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second highest cause
of cancer death in the UK. Most cases occur in people over 50 years and CRC often co-exists with other lifestyle
related disorders including obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). These
diseases share risk factors related to the metabolic syndrome including large body size, abnormal lipids and
markers of insulin resistance indicating common aetiological pathways.
Methods/Design: This 3 year study will be a two-arm, multicentre, randomised controlled trial comparing the
BeWEL lifestyle (diet, physical activity and behaviour change) programme against usual care. The pre-trial
development will take 6 months and participants will be recruited over a 12 month period and undertake the
intervention and follow up for 12 months (total 24 months recruitment and intervention implementation) with a
further 6 months for data collection, analysis and interpretation.
Four hundred and fifty two participants who have had a colorectal adenoma detected and removed (through the
national colorectal screening programme) will provide 80% power to detect a weight loss of 7% over 12 months.
Primary outcomes are changes in body weight and waist circumference. Secondary outcomes will include
cardiovascular risk factors, psycho-social measures and intervention costs.
Discussion: The results from this study will enhance the evidence base for lifestyle change in patients at higher
risk of chronic disease including obesity related cancers.
International Standard Randomised Controlled Trials No: ISRCTN53033856
Background
Colorectal cancer (CRC) is a major public health pro-
blem. It is the third most commonly diagnosed cancer
and the second cause of cancer death in the UK [1].
Most cases (95%) occur in people over 50 years and
CRC often co-exists with other lifestyle related disorders
including obesity, type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD) [2,3].
Consistent with preventive effects for CVD and T2DM
[4], there is evidence that physical activity protects
against CRC, and that high levels of body fat (BMI >23
kg/m2) or a large waist circumference are associated
with increased risk [5]. There is also evidence that red
and processed meat and high alcohol intake increase
CRC risk [5]. Thus a number of modifiable risk factors
can be identified and addressed with potential benefit to
risk of CRC, and proven benefit on risk reduction of
T2DM and CVD.
Both public health and individual approaches are
needed to assist health behaviour change and this is par-
ticularly important for individuals who are at risk of
developing obesity related co-morbidities. The NHS
CRC screening programme is increasing the identifica-
tion of adenomas and the current programme roll-out
provides a timely opportunity to offer risk factor reduc-
tion advice to older adults from all social and ethnic
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(and other diet related conditions). The Scottish CRC
screening data show that adenomas are most common
in adults from areas of high deprivation (46% of colo-
noscopies vs 29% in adults from areas of low depriva-
tion). Indeed, screen-positive men from the poorest
backgrounds have a 50% chance of having an adenoma
detected at colonoscopy (personal communication from
R.J.C. Steele) and that is despite poorer uptake of
screening in these areas.
Diabetes prevention trials have shown that lifestyle
interventions that achieve a weight loss of 7% of initial
body weight and at least 150 min/week of moderate
intensity activity in adults with a BMI >25 kg/m2
reduce the incidence of T2DM [6-8] and have favour-
able effects on CVD risk factors [9]. It is likely that
these lifestyle changes would also influence obesity-
related neoplasia. Jacobs et al [10] identified obesity as a
risk factor for short-interval (follow up 3 years) develop-
ment of colorectal adenomas, particularly in men.
Although it is unclear at what stage obesity impacts on
adenoma development, there is evidence that adenoma
risk increases among adults who have gained weight in
the 5 years prior to colonoscopy [11]. Recent work from
Japan which followed up 1,650 adults reported that the
incidence of adenoma in those who had lost weight in
the one year follow up period was significantly lower
than in those who had maintained or gained weight
[12]. The case for exploring cost-effective weight reduc-
tion strategies is also supported by long term follow-up
trials of obesity surgery showing significant reduction in
cancer mortality [13]. In addition, recent evidence has
demonstrated that increasing physical activity in men
aged over 50 shows a graded reduction in total mortal-
ity risk [14].
The major government strategy aimed at decreasing
CRC burden is focused on early detection of the disease
and national CRC screening programmes. CRC screening
can also detect adenomas, which are the identifiable pre-
cursor lesions of CRC which can be removed by endo-
scopic procedures. This reduces the risk of subsequent
cancer but the underlying (modifiable) risk factors which
influence the development of new adenomas remain [15].
Current evidence suggests that the risk of new adenomas
is around 40% after 3 years, although this may be higher
in the morbidly obese [16]. Clinical encounters with
healthy individuals who have had adenomas removed
present an opportunity for risk factor reduction.
Study Objectives
Primary Outcomes
The main aim of the study is to evaluate the impact of a
lifestyle (diet, physical activity and behaviour change)
intervention programme ("BeWEL”) on body weight
change and waist circumference in healthy individuals
attending routine NHS clinics who have had pre-cancer-
ous bowel polyps removed.
Secondary outcomes
We will examine whether there is a relationship between
response to the BeWEL intervention and the partici-
pant’s classification on the Scottish Index of Multiple
Deprivation (SIMD) [17]. Cardiovascular risk factors will
also be examined for changes in blood lipids, homeosta-
sis model assessment (HOMA), as a measure of insulin
resistance, blood pressure and Glycated haemoglobin
(HbA1c). Lifestyle habits, self-assessed health, self-effi-
cacy, perceived acceptability of the programme, and
intervention costs will also be assessed.
Methods/Design
Ethical approval for the study has been received from
NHS Tayside Regional Ethics Committee (see later). All
participants will receive a written participant informa-
tion sheet explaining the trial and all will be asked to
give written consent.
Study/trial design
The study will be a two-arm, multicentre, randomised
controlled trial comparing the BeWEL intervention with
usual care and will last for 3 years.
Treatment period and follow up
All baseline measures will be made prior to group allo-
cation, and follow up measures (at 3 and 12 months)
will be subject to a strict protocol with researchers blind
to group allocation. Intervention group participants will
have face-to-face intervention contact on 3 occasions
during the first 3 months followed by bi-monthly (tele-
phone/email) contact until 12 months. Participants in
both groups will be asked to complete a single page exit
questionnaire on the acceptability of the study
procedures.
Measures of CVD risk (lipids, HOMA and blood pres-
sure) have been included as part of good clinical prac-
tice (given that many of these individuals will have early
signs of metabolic syndrome or CVD) as a check for
unintended consequences. Secondary outcomes are not
part of our sample size calculations (which is normal
practice) but we believe they will add value without
excessive participant burden and will be available for
future meta-analysis/review purposes and hypothesis
generating in this area.
Process Evaluation
Programme acceptability will be explored post-interven-
tion with in-depth exit interviews with a random sample
of 30 intervention participants. Interviews will cover
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ing the programme, the extent to which these were met
or not by their subsequent experiences, and factors
influencing their ability to make the recommended life-
style changes.
Measures/assessment instruments
Measures at all outcome points will be completed face-
to-face. Details of the outcomes that are collected at the
different time points are detailed in Table 1 below.
Centre/practice and/or participant selection
The intervention study will be delivered in 3 centres
(Tayside, Forth Valley and Ayrshire and Arran) and the
lead colorectal cancer clinicians at each site have estab-
lished that the colorectal/endoscopy teams are willing to
participate in this trial.
Inclusion criteria
Screening adenoma patients aged 50 to 74 years with a
BMI >25 Kg/m
2 who are physically able to undertake
exercise requirements and are able to provide informed
consent.
Exclusion criteria
Patients will not be eligible for the trial if they have a
normal colonoscopy, are insulin-dependent patients with
diabetes or are diagnosed with cancer.
Participant Recruitment
All patients who undergo screening colonoscopy pro-
cedures and are found to have benign adenomas are
sent a letter reassuring them of their findings and re-
enforcing the importance of follow up surveillance
(further colonoscopy). The first contact about the
study will be made at this point. This will comprise a
second (brief) letter from the colorectal cancer sur-
geon, enclosed with the screening results, endorsing
the study and encouraging them to read an informa-
tion sheet which will be sent by the study team within
two weeks. The participant information sheet will be
sent by the research nurse along with a covering letter
of invitation, a reply slip and a pre-paid reply envelope.
Those who state their interest in taking part will be
screened for eligibility over the telephone, and (if eligi-
ble) invited to the study centre (with a spouse or other
family support member) to provide informed consent
and undergo baseline measures. The trial manager will
be responsible for ensuring that allocation at each site
follows standard procedures with even distribution into
each condition.
All participants will be provided with written lifestyle
advice (British Heart Foundation leaflet: So you want to
lose weight for good: A guide to losing weight for men
and women) so that it is less obvious to participants
which arm of the trial they have been allocated to. Staff
responsible for recruitment and follow-up will not deli-
ver the intervention. The intervention will be delivered
by trained lifestyle counsellors. All baseline measures
will be made prior to group allocation and follow up
measures will be subject to a strict protocol with
researchers blind to group allocation.
Informed consent
Those who state their interest in taking part will be
given any further information they require and, if eligi-
ble, invited to the study centre (with a spouse or other
family support member) to provide informed consent
and undergo baseline measures.
Registration
A record of individuals who were invited to participate
in the trial, whether consent to be contacted by tele-
phone was given or declined, and their eligibility will be
kept by the research nurse who initially contacts poten-
tial participants. The research nurse will also keep a log
of any individuals who declined at the trial consent
meeting. A case report form (CRF) will be completed
for all consented individuals. Details of a nominated
contact (e.g. spouse or friend) will also be collected to
facilitate participant follow-up. The research nurse will
use the trial data management system to enter and store
data on all eligible individuals. Recruitment information
will also be monitored at regular intervals by comparing
this to the number being approached and numbers
declining.
Table 1 Outcome Measures (B = baseline; 3F = 3 month
follow-up, 12F = 12 month follow-up)
Measure When
Primary Outcome
BMI (weight &
height)
Calibrated scales & stadiometer B, 3F, 12F
Waist circumference Tape measure B, 3F, 12F
Lipid profile Blood test B, 3F, 12F
Blood pressure Sphygmonanometer B, 3F, 12F
HOMA Blood test B, 3F, 12F
HbA1c Blood test B,
3F, 12F
Blood test B, 3F, 12F
Secondary Outcomes
Diet DINE diet questionnaire B, 3F, 12F
Physical activity Sensewear physical activity
monitor (7 days)
B, 3F, 12F
General health and
self efficacy
Questionnaire B, 3F, 12F
Programme
acceptability
In-depth interview with clinic and
counselling staff
Post
intervention
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Individuals can decline to consent to taking part in the
study and their medical care will not be affected.
Withdrawal and loss to follow-up
Individuals have the right to withdraw consent for parti-
cipation in any aspect of this trial at any time. Care
from other services will not be affected at any time by
declining to participate or withdrawing from the trial.
We will make every effort to reduce loss to follow-up.
We will visit participants at home should they wish,
which we expect to improve response rates and loss to
follow-up. If a participant misses one follow-up we will
try to arrange with them on two further occasions. We
will reimburse any travel costs.
Trial intervention
The Intervention Group (IG)
Intervention participants will receive the “BeWEL” per-
sonalised intervention programme, personal (body
weight) scales, and invitations to undertake supervised
monthly body weight. The BeWEL personalised, multi-
ple contact, intervention programme will be largely
based on the US diabetes prevention programme
(http://www.bsc.gwu.edu/dpp/index.html), which
includes (a) goal-setting for weight, activity, and calorie
intake; (b) self-monitoring to achieve these goals; (c) fre-
quent contact to provide accountability and sustain
focus; (d) use of problem-solving and other “toolbox”
strategies to address goals and potential barriers to
achieving them; and (e) emphasis on managing indivi-
dual high-risk situations. The approach will take parti-
cular care to emphasise the importance of regular self-
weighing which is widely associated with greater weight
loss and weight prevention (showing a 1 to 3 BMI unit
advantage over individuals who do not self-weigh fre-
quently) [18,19].
The Usual Care (comparison group)
Usual care participants will be given a general leaflet on
healthy lifestyle that is widely available in the NHS set-
ting. This will ensure that all participants receive some
lifestyle advice which at the moment is given out on an
ad hoc basis. Whilst not a ‘no treatment’ control group,
‘no treatment’ is not current practice; individuals may
receive lifestyle information. We will collect weight
information in the comparison group, which is not a
routine measurement for this group of patients.
Although we recognise that this may influence beha-
viour in the comparison group, we anticipate that the
effect will be small and it is essential for collecting data
for the primary outcome.
Participants in both groups will be reminded of their
follow-up appointments by advance telephone call.
Figure 1 below illustrates the participant pathway
through the trial.
Serious adverse events
No serious adverse events (SAE) are anticipated. How-
ever if any SAE occur, this will be drawn to the immedi-
ate attention of the participant’s General Practitioner.
Statistical considerations
Randomisation
Once individuals have consented to the study and had
baseline measurements taken they will then be randomly
allocated by a permuted-block technique, with block
sizes of four or eight and with stratification by trial site
into the usual care group or an intervention group. Ran-
domisation will be done by email (agreed protocol in
place to ensure this procedure can be undertaken during
all office hours) to the trial centre.
Sample size
To demonstrate a 7% weight loss with 80% power it is
estimated that 133 participants would be required to
complete each arm of the study. The sample size is based
on the aim of achieving 7% weight loss at 12 months
which has been demonstrated to be clinically effective in
diabetes prevention. In the Bowel Health to Better Health
(BHBH) study [20] the mean body weight was 85.4 (±
17.3) kg. Allowing for a drop out rate of 16%, this would
mean enrolment of 158 into each arm of the study. With
a 70% recruitment rate this would require 226 eligible
subjects in each arm. It is estimated that 81% of clinic
subjects would meet the eligibility criteria thus a pool of
558 subjects are required from which to recruit for the
study. Current figures suggest that 200 patients are diag-
nosed with adenoma each year at each of the 3 participat-
ing sites, thus a one year recruitment period should allow
for any variation in the estimated figures and easily per-
mit recruitment to the intended design.
Analysis
Main analysis
Randomisation will be stratified by site. The primary
analyses will be carried out under intention-to-treat but
secondary analyses will explore the effect of treatment
received. The main analyses will involve standard two-
sample comparisons (parametric or nonparametric as
dictated by the distribution of the data) looking at effect
sizes at 3 and 12 months. As these are mainly continu-
ous outcomes, this will involve t-tests or Mann-Whitney
t e s t sa sw e l la sr e p e a t e dm e a s u r e s .A l la n a l y s e sw i l lb e
stratified by centre. Differences by site will be explored
and, if appropriate, the site can be entered in a mixed
model as a random effect. The balance of characteristics
between treatment and control arms will be tabulated
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these in linear regression models. Pre-specified subgroup
analyses for socioeconomic status will be carried out by
including the appropriate treatment interaction term.
Thus sub-group analyses will be exploratory and
hypothesis generating rather than hypothesis testing.
Qualitative analysis
A thematic analysis of interview transcripts will be
undertaken, exploring such themes as what factors influ-
ence decisions to engage in the programme, how uptake
is influenced by socio-economic status, the practical bar-
riers and opportunities for facilitating physical activities
Random allocation to the intervention group or the usual care group 
Intervention (n=158)  Usual care (n=158) 
Will receive a general leaflet on healthy 
lifestyle plus BeWEL personalized 
intervention program, personal body 
weight scales, supervised monthly body 
weight recordings 
 
Will receive a general leaflet on 
healthy lifestyle 
3 face-to-face visits in the first 3 months 
             (n=133)           12 month follow-up                       (n=133) 
Monthly telephone/email contacts between 
months 3 and 12 
Interested individuals will be telephone screened and (if eligible) invited to the study centre to provide informed consent and 
undergo baseline measures (est. n=316)
Healthy individuals who have undergone screening colonoscopy procedures for benign adenomas will be informed about the 
study (in brief) by the colorectal cancer surgeon when sent their colonoscopy results.  A full invitation by the research nurse 
will then follow within the next 2 weeks (est. n=452) 
Lost to follow up est. 
n=25 
Lost to follow 
up est. n=25 
Do not wish to participate est. n=136 
Main inclusion: Adenoma patients aged 50 to 74 years, with a BMI >25kg/m
2, physically able to undertake exercise 
requirements. 
Main exclusions: normal colonoscopy or cancer diagnosis 
Exit questionnaire and in-depth interview 
Figure 1 Participant flow diagram.
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ability of the programme to participants and families.
Economic analysis
The economic analysis will take the form of a cost-con-
sequence analysis (CCA), in which all potential costs
and benefits will be identified, measured and valued
where appropriate (differences expected between
groups) and feasible. The analysis will be undertaken
from both an NHS and societal perspective. For inter-
ventions that require individual behaviour change to be
successful, it is particularly important to consider the
costs and benefits from the perspective of individual
participants and their families [21]. These will be
explored in the context of the CCA and in more depth
in the post-intervention interviews. CCA also allows for
a flexible presentation of results in contexts where there
is more than outcome of interest.
The NHS costs of the intervention will be assessed
according to the intervention protocol, with sampling to
assess length and frequency of contacts, fidelity of deliv-
ery and staff time. The analysis will also be informed by
the qualitative part of the research. NHS benefits related
to reduced service use as a consequence of healthier
lifestyles will be modelled from secondary data and rele-
vant literature. This modelling will allow estimates to be
made of the potential longer term benefits of behaviour
change.
Data storage & retention
Data management will be handled by the Tayside Clini-
cal Trials Unit with data being held according to GCP
requirements. As per MRC requirements, data will be
held for a minimum of ten years from completion of the
project.
Ethical approval, research governance and data
access
Ethical approval was obtained from the Tayside
Research Ethics Committee via IRAS, (Tayside Commit-
tee on Medical Research Ethics B. Ref No. 10/S1402/34,
Approval granted 23rd July 2010) with other participat-
ing centres providing site-specific approval as per nor-
mal IRAS procedures. NHS Research and Development
(R&D) approval was obtained from all participating
NHS Boards prior to the start of the trial (Tayside R&D
Project ID 2010ON16), (Ayrshire and Arran R&D Pro-
ject ID 2010AA047) and (Forth Valley R&D Reference
FV539). Further advice and support on governance and
good clinical practice (GCP) issues will be provided by
the Tayside Clinical Trials Unit. BeWEL will make use
of the University of Dundee’s Standard Operating Proce-
dures for tasks such as obtaining consent, managing and
archiving data, access to trial data, training and how to
handle breaches of GCP. The trial has been submitted to
The International Standard Randomised Controlled Trials
(ISRCT) and allocated the number ISRCTN53033856.
Study/trial sponsorship
The University of Dundee is the sponsor of this trial.
Discussion/Rationale for current study
Behaviour change programmes that target high risk
groups can be more effective at the individual level than
those targeting the population at large [22]. It is possible
that adults who have had a ‘health scare’ (e.g. diagnosis
of adenoma) experience a ‘teachable moment’ [23] in
which they will be more motivated to engage in and
adhere to lifestyle advice. Current evidence does not
suggest that adenoma diagnosis per se is associated with
a change in health behaviours [24]. This client group
has been reported to have low levels of nutrition knowl-
edge and little awareness of the link between diet and
cancer [25]. However, there is evidence that they would
welcome advice on healthy eating, with face-to-face
mode being preferred [26]. Weh a v ea l s od e m o n s t r a t e d
that diet and activity in this group is inconsistent with
current guidelines [27].
The NHS setting provides i) an existing framework for
obesity intervention work particularly when co-morbid-
ities (including colorectal adenomas) are present, ii)
access to clinicians who can endorse behaviour change
in healthy volunteers who have had a health scare and
are potentially motivated towards prevention action, and
iii) the potential for long term follow-up. The advantage
of a hospital setting is that it provides a central location
that all participants will have visited and therefore know
the route and location. This is important for men who
may rarely have visited their primary care practice. In
addition, the hospital base re-enforces clinical endorse-
ment and the importance of the desired outcome. The
results from the recent TIME2ACT [27] study of
increasing physical activity in patients with diabetes sug-
gests that response is higher when interventions are
delivered in a hospital setting because of the perceived
medical endorsement and the sense that the interven-
tion is an integrated part of care. From a practical per-
spective it increases the likelihood of this type of
intervention being feasible (e.g. it would be difficult to
follow up individual patients from a large geographical
area who could be followed upi nt h ec o m m u n i t y ) ,a n d
there are existing NHS obesity services in the hospital
outpatient setting.
The results from this study will assess the impact of
the BeWEL intervention on body weight and CVD risk.
The study will also provide a platform (feasibility evi-
dence) for the long-term evaluation of BeWEL on ade-
noma development in high risk, healthy participants and
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be initiated in routine NHS clinics. Furthermore the work
will increase understanding of participant engagement,
barriers, opportunities and experiences of lifestyle manage-
ment programmes, and examine the cost-effectiveness of
the intervention procedures in this NHS setting.
The results of the study have implications for the pre-
vention and delay of onset of all obesity related chronic
diseases that are major causes of morbidity and death in
the UK. The study is of direct relevance to the NHS and
has the potential to significantly enhance current gov-
ernment action on the prevention of a range of obesity-
related disorders. The results will also have implications
for other studies that aim to transfer research findings
into routine care. The process study data (participant
experience) will be relevant to research beyond obesity
management.
Beyond the end of the project, 5-year follow-up mea-
sures of adenoma occurrence will be assessed from rou-
tine NHS screening data collection. Thus, although not
powered to detect disease end-points, the BeWEL data
will provide indicative data (feasibility data on ability to
achieve weight loss) of a lifestyle trial for chronic disease
outcomes.
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